Q4 Earnings Estimate for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Leerink Partnrs raised their Q4 2025 EPS estimates for shares of Illumina in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings per share of $1.27 for the quarter, up from their previous forecast of $1.24. The consensus estimate for Illumina’s current full-year earnings is $4.13 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $5.15 EPS.

Several other research analysts have also issued reports on the stock. TD Cowen upped their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. UBS Group increased their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley lowered their price target on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Trading Down 4.2 %

Shares of Illumina stock opened at $134.46 on Thursday. The company has a 50 day simple moving average of $139.06 and a two-hundred day simple moving average of $134.26. The firm has a market cap of $21.32 billion, a PE ratio of -13.47 and a beta of 1.11. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 earnings per share.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently made changes to their positions in ILMN. Empowered Funds LLC raised its position in Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares during the period. Caprock Group LLC increased its stake in shares of Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Moors & Cabot Inc. lifted its position in Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after purchasing an additional 95 shares in the last quarter. Finally, Carson Advisory Inc. grew its holdings in Illumina by 3.8% during the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock valued at $360,000 after purchasing an additional 102 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.